Evidence map›Paper›PMID 30656384›Full record

ArticleCancer immunology, immunotherapy : CII2019

Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice.

Elodie Pliquet, Claude Ruffie, Marie Escande, Jessie Thalmensi, Valérie Najburg, Chantal Combredet, Thomas Bestetti, Marion Julithe, Christelle Liard, Thierry Huet and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Elodie PliquetInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France. elodie.pliquet@invectys.com.ORCID http://orcid.org/0000-0003-4242-8569
Claude RuffieViral Genomics and Vaccination Unit, Institut Pasteur, CNRS-UMR 3965, Paris, France.
Marie EscandeInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.
Jessie ThalmensiInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.
Valérie NajburgViral Genomics and Vaccination Unit, Institut Pasteur, CNRS-UMR 3965, Paris, France.
Chantal CombredetViral Genomics and Vaccination Unit, Institut Pasteur, CNRS-UMR 3965, Paris, France.
Thomas BestettiInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.
Marion JulitheInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.
Christelle LiardInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.
Thierry HuetInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.ORCID http://orcid.org/0000-0001-9842-591X
Simon Wain-HobsonInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.ORCID http://orcid.org/0000-0002-6406-3858
Frédéric TangyViral Genomics and Vaccination Unit, Institut Pasteur, CNRS-UMR 3965, Paris, France.ORCID http://orcid.org/0000-0002-5937-5654
Pierre Langlade-DemoyenInvectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.
Centre National de la Recherche Scientifique · FRParis Biotech Santé · FR

Funding

Association Nationale de la Recherche et de la Technologie 2012/0152
6 · The paper itself

Abstract

Cancer immunotherapy is seeing an increasing focus on vaccination with tumor-associated antigens (TAAs). Human telomerase (hTERT) is a TAA expressed by most tumors to overcome telomere shortening. Tolerance to hTERT can be easily broken both naturally and experimentally and hTERT DNA vaccine candidates have been introduced in clinical trials. DNA prime/boost strategies have been widely developed to immunize efficiently against infectious diseases. We explored the use of a recombinant measles virus (MV) hTERT vector to boost DNA priming as recombinant live attenuated measles virus has an impressive safety and efficacy record. Here, we show that a MV-TERT vector can rapidly and strongly boost DNA hTERT priming in MV susceptible IFNAR/CD46 mouse models. The cellular immune responses were Th1 polarized. No humoral responses were elicited. The 4 kb hTERT transgene did not impact MV replication or induction of cell-mediated responses. These findings validate the MV-TERT vector to boost cell-mediated responses following DNA priming in humans.

Indexed as

Genetic VectorsImmunity, CellularMeasles virusAnimalsCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineChlorocebus aethiopsCytokinesCytotoxicity, ImmunologicEpitopes, T-LymphocyteHumansImmunizationImmunization, SecondaryMiceCancer VaccinesCytokinesEpitopes, T-LymphocyteTelomeraseTERT protein, humanVaccines, DNACancerhTERTImmunotherapyMeasles virus vaccineT-cell responses

Identifiers

PMID30656384
PMCPMC11028090
OpenAlexW2910342048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.